Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

doi:10.1093/jjco/hyt130

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药理学第一研究室

	Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
	Huang, Ou 2; Jiang, Min 2; Zhang, Xi 2; Xie, Zuoquan1 ; Chen, Xiaosong 2; Wu, Jiayi 2; Liu, Hongchun1 ; Shen, Kunwei 2
刊名	JAPANESE JOURNAL OF CLINICAL ONCOLOGY
	2013-11
卷号	43 期号:11 页码:1064-1072
关键词	grb14 breast cancer locally advanced neoadjuvant chemotherapy prognosis
ISSN号	0368-2811
DOI	10.1093/jjco/hyt130
文献子类	Article
英文摘要	Objective: Growth factor receptor-binding protein 14, a new member of noncatalytic adaptor proteins family, has been shown to be upregulated in breast cancer. We investigated the prognostic value of growth factor receptor-binding protein 14 expression in breast cancer patients treated with neoadjuvant chemotherapy. Methods: Primary breast cancer specimens were taken from locally advanced breast cancer patients in a Phase II clinical trial of neoadjuvant chemotherapy and the expression pattern of growth factor receptor-binding protein 14 was determined by immunohistochemistry. Kaplan-Meier analysis and Cox regression model were used to assess disease-free and overall survival, according to the expression of growth factor receptor-binding protein 14 in tumor cells. Results: Our result showed that growth factor receptor-binding protein 14 was highly expressed in 23.1% of breast cancer sections, and high expression of growth factor receptor-binding protein 14 was significantly associated with better disease-free (P = 0.016, hazard ratio 0.07, 95% confidence interval 0.06-0.08) and overall survival (P = 0.004, hazard ratio 0.02, 95% confidence interval 0.02-0.03), compared with the low-expression group. Multivariate analysis indicated that high expression of growth factor receptor-binding protein 14 was an independent good prognostic factor for both disease-free (P = 0.04, hazard ratio 0.37, 95% confidence interval 0.14-0.98) and overall survival (P = 0.03, hazard ratio 0.11, 95% confidence interval 0.10-0.82). Conclusions: High expression of growth factor receptor-binding protein 14 in breast cancer cells may help to identify low-risk patients for additional therapies after neoadjuvant chemotherapy.
资助项目	National Natural Science Foundation of China[81202087] ; National Natural Science Foundation of China[81172520] ; National Natural Science Foundation of China[81202088] ; Leading Academic Discipline Project of Shanghai Municipal Education Commission[J50208] ; Shanghai Science and Technology Committee[12ZR1446400] ; Shanghai Science and Technology Committee[12140901503] ; Shanghai Charity Cancer Research Center[00000000]
WOS关键词	ADAPTER PROTEIN GRB14 ; RECEPTOR ; EXPRESSION ; MICROARRAY ; MODULATOR ; INSULIN ; FAMILY ; RISK
WOS研究方向	Oncology
语种	英语
出版者	OXFORD UNIV PRESS
WOS记录号	WOS:000326647400002
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/277401]
专题	药理学第一研究室
通讯作者	Shen, Kunwei
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, Shanghai 200031, Peoples R China 2.Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200025, Peoples R China;
推荐引用方式 GB/T 7714	Huang, Ou,Jiang, Min,Zhang, Xi,et al. Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY,2013,43(11):1064-1072.
APA	Huang, Ou.,Jiang, Min.,Zhang, Xi.,Xie, Zuoquan.,Chen, Xiaosong.,...&Shen, Kunwei.(2013).Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.JAPANESE JOURNAL OF CLINICAL ONCOLOGY,43(11),1064-1072.
MLA	Huang, Ou,et al."Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy".JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43.11(2013):1064-1072.